Monoclonal Antibodies in Asthma

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2006-02-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.


Scope

  • Evaluation of the market potential and dynamics of Xolair, currently the only marketed respiratory monoclonal antibody
  • Examination of the key mediators in asthma and the evidence supporting their role
  • Identification and evaluation of fifteen monoclonal antibodies currently in preclinical or clinical development to treat asthma
  • Assessment of drivers and resistors of using monoclonal antibodies in the severe asthma market


    • Report Highlights
    Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified.

    Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator.

    Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market.


    Reasons to Purchase

  • Evaluate the current state of the monoclonal antibodies market and the market capture potential for these products in severe asthma
  • Assess the key technological trends to capitalize on opportunities in the respiratory monoclonal antibody sector
  • Identify possible targets to focus monoclonal antibody design

    • Table of Contents

    Other users found this report page using the following search terms: monoclonal antibodies asthma asthma monoclonal antibodies antibody market xolair atopic cons non role

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.